PRGN-3005是一种首创(first-in-class)疗法,利用了Precigen公司UltraCAR-T治疗平台开发。PRGN-3005 UltraCAR-T是一种自体嵌合抗原受体T(CAR-T)细胞疗法,利用非病毒基因递送技术制造,目前正被评估治疗晚期复发性铂耐药卵巢癌、输卵管癌或...
UltraCAR-T cells are manufactured at medical center's cGMP facility using autologous T cells and administered back to patient only one day after gene transfer.PRGN-3005 UltraCAR-T cells simultaneously co-express (i) a CAR specifically targeting MUC16 which is highly expressed on ovarian tumors ...
PRGN-3005是一种首创(first-in-class)疗法,利用了Precigen公司UltraCAR-T治疗平台开发。PRGN-3005 UltraCAR-T是一种自体嵌合抗原受体T(CAR-T)细胞疗法,利用非病毒基因递送技术制造,目前正被评估治疗晚期复发性铂耐药卵巢癌、输卵管癌或原发性腹膜癌的治疗。 PRGN-3005利用了Precigen公司变革性的UltraCAR-T治疗平台,...